COMPASS Pathways plc (NASDAQ:CMPS) Short Interest Update

COMPASS Pathways plc (NASDAQ:CMPS) was the target of a large increase in short interest in September. As of September 30th, there was short interest totalling 6,390,000 shares, an increase of 8.9% from the September 15th total of 5,870,000 shares. Based on an average daily trading volume, of 516,300 shares, the days-to-cover ratio is currently 12.4 days.

Insider Buying and Selling at COMPASS Pathways

In other COMPASS Pathways news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $6.05, for a total transaction of $16,093,000.00. Following the completion of the sale, the insider now directly owns 6,905,774 shares of the company’s stock, valued at $41,779,932.70. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 4.25% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Tidal Investments LLC boosted its stake in COMPASS Pathways by 43.6% during the first quarter. Tidal Investments LLC now owns 19,082 shares of the company’s stock worth $159,000 after buying an additional 5,795 shares during the period. AdvisorShares Investments LLC boosted its stake in shares of COMPASS Pathways by 13.5% during the second quarter. AdvisorShares Investments LLC now owns 60,882 shares of the company’s stock valued at $362,000 after purchasing an additional 7,243 shares during the period. Blue Trust Inc. purchased a new stake in shares of COMPASS Pathways during the second quarter valued at $81,000. Green Alpha Advisors LLC purchased a new stake in shares of COMPASS Pathways during the third quarter valued at $99,000. Finally, Kennedy Capital Management LLC purchased a new stake in shares of COMPASS Pathways during the first quarter valued at $139,000. 46.19% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CMPS has been the topic of several research reports. Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a research report on Monday, September 9th. Canaccord Genuity Group reduced their price target on shares of COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating on the stock in a research report on Friday, August 2nd. Royal Bank of Canada restated an “outperform” rating and issued a $23.00 price target on shares of COMPASS Pathways in a research report on Tuesday, September 10th. Finally, HC Wainwright restated a “buy” rating and issued a $120.00 price target on shares of COMPASS Pathways in a research report on Friday, August 23rd. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $47.40.

COMPASS Pathways Trading Down 0.2 %

NASDAQ CMPS traded down $0.01 on Thursday, hitting $6.27. 603,085 shares of the stock were exchanged, compared to its average volume of 547,729. The company has a debt-to-equity ratio of 0.13, a quick ratio of 12.03 and a current ratio of 12.03. The stock has a fifty day moving average price of $6.82 and a two-hundred day moving average price of $7.32. The firm has a market capitalization of $428.75 million, a P/E ratio of -2.65 and a beta of 2.26. COMPASS Pathways has a 52-week low of $5.01 and a 52-week high of $12.75.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.03). During the same period in the prior year, the firm earned ($0.62) EPS. Research analysts forecast that COMPASS Pathways will post -2.35 EPS for the current fiscal year.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.